Table 2.
Comparison of symptomatic infection odds after full vaccination with mRNA-1273 versus BNT162b2 using a test-negative design
| Time period | mRNA-1273 | BNT162b2 | |
|---|---|---|---|
| Study duration Dec 1, 2020– Sept 22, 2021 | positive tests (cases) | 814 | 2,407 |
| negative tests (controls) | 6,294 | 13,668 | |
| crude odds ratio (95% CI) | 0.734 (0.675, 0.799) | ||
| adjusted odds ratio (95% CI) | 0.604 (0.546, 0.667) | ||
| Early epoch Dec 1, 2020– May 31, 2021 | positive tests (cases) | 24 | 118 |
| negative tests (controls) | 332 | 1,085 | |
| crude odds ratio (95% CI) | 0.665 (0.421, 1.05) | ||
| adjusted odds ratio (95% CI) | 0.414 (0.232, 0.74) | ||
| Late epoch Jul 1, 2021–Sept 22, 2021 | positive tests (cases) | 772 | 2,242 |
| negative tests (controls) | 5,706 | 12,171 | |
| crude odds ratio (95% CI) | 0.734 (0.673, 0.802) | ||
| adjusted odds ratio (95% CI) | 0.611 (0.551, 0.677) | ||
For each time period, the number of cases and controls contributed by the two populations is shown. To compare the odds of symptomatic infection after full vaccination, we calculated the crude odds ratio and an adjusted odds ratio using conditional logistic regression.